AlphaMa and Lilly Collaborate on Drug Discovery Based on Intelligent DNA-Encoded Libraries
AlphaMa Biotech (“AlphaMa”) is pleased to announce that the company has entered into a research collaboration with Eli Lilly and Company (“Lilly”) to utilize AlphaMa’s proprietary intelligent DNA-encoded libraries (“iDEL”) for drug discovery and development in selected therapeutic areas.
AlphaMa has established a unique platform that integrates DNA-encoded library (DEL) and Artificial Intelligence (AI) for small molecule drug discovery. With AI-guided libraries design, the platform enables fast screening of billions of diversified scaffolds for novel hits identification, optimization for leads with better target engagement, selectivity, and ADME/T properties. This collaboration will apply AlphaMa’s screening platform in Lilly’s drug research and development programs.
Suzhou AlphaMa Biotechnology Co., Ltd. is a drug R&D company driven by AI and big data, mainly engaged in innovative drug research and development, candidate drug transfer, and related technical development collaboration. AlphaMa applies artificial intelligence to all drug developing stages, especially the interactive application with DEL to establish a unique iDEL platform. Utilizing this platform, AlphaMa is committed to developing small molecule drugs for cancerous, neurological, metabolic, and infectious diseases. Their goal is to accelerate drug R&D and bring clinically needed medications to society as soon as possible, using AI and DEL technologies.